Rio de Janeiro, Brazil, 11 September 2023 — The 2023 annual meetings of the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI) were held in Rio de Janeiro, Brazil from 2-4 August 2023 (SOLACI-SBHCI 2023), drawing interventional cardiology experts from around the world. MicroPort® presented clinical applications of its interventions and devices, which drew many experts.
Within the conference’s symposiums, experts shared the first batch of clinical cases involving coronary interventional surgeries guided by μFR technology conducted in Latin America, and discussed the clinical application of an angiographic quantitative flow ratio system.
Focusing on the domain of coronary intervention, MicroPort® shared the implantation procedures of its Firehawk® and Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent Systems. In the field of Transcatheter Aortic Valve Implantation (TAVI), physicians from Latin American countries shared clinical data and case studies of the VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System, developed by MicroPort CardioFlow™.
The SOLACI-SBHCI 2023 journey of VitaFlow Liberty® began with a recorded TAVI operation, conducted by Professor Matias Sztejfman and his team from the Sanatorio Finochietto Center in Argentina.
Subsequently, during the symposium hosted by CardioFlow™, attending experts shared the clinical application of complex cases surrounding the product features of VitaFlow Liberty®.
Professor Matias Sztejfman shared registration data and follow-up condition of the 28 patients at his center. In an elderly patient group with an average age 79.2±8.2 years, the procedure was 100% successful, and the 30-day mortality rate was 0%. With a lower occurrence of newly developed conduction abnormalities, pacemaker implantation needs, postoperative myocardial infarction, or coronary occlusion, the VitaFlow® series transcatheter aortic valve demonstrated the tangible benefits for patients in its clinical applications, as well as the advantages of its design, which includes a larger effective valve orifice area and lower transvalvular pressure gradient.
Similarly, a presentation by Professor Pablo D. Charry from the CardioVascular Medicine Center in Colombia showed a complex TAVI and percutaneous coronary intervention case involving an elderly patient. The patient was diagnosed with severe aortic valve calcification accompanied by moderate regurgitation and comorbid coronary heart disease. During this successful procedure, a coronary intervention was initially performed, followed by the implantation of the delivery system through the femoral artery to its ideal position for precise release.
Supplementing these presentations was Professor Pablo Lamelas from Instituto Cardiovascular de Buenos Aires Hospital in Argentina, who noted that as patients with valve heart diseases featuring high surgical risks and complex anatomical structures increase, VitaFlow Liberty® will become a superior choice for TAVI.
By attending the SOLACI-SBHCI 2023 conference, MicroPort® was able to captivate experts by demonstrating its exceptional clinical performance and cutting-edge solutions for coronary intervention and transcatheter aortic valve replacement. As a leading medical device group, MicroPort® will continue to merge the techniques and experiences of top experts worldwide and is committed to the research and development of high-end, innovative medical devices to provide more trustworthy and universal access to state-of-the-art solutions that prolong and reshape patient lives everywhere.
Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical devices company with over 12,000 employees worldwide. We provide solutions across twelve therapeutic areas, including orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 25 years we have been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. Our therapeutic solutions are available in more than 100 countries and over 20,000 hospitals around the world, and today. Proudly, today every 6 seconds, a patient around the world benefits from a MicroPort® life-changing solution.
More information is available at www.microport.com.
Founded in Shanghai in 2015, MicroPort® CardioFlow (MicroPort CardioFlow Medtech Corporation; HKEX: 02160), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart disease. Our self-developed second-generation Transcatheter Aortic Valve Implantation (TAVI) product VitaFlow Liberty® is the world’s only commercialized motorized retrievable system. In addition to the TAVI products, we have also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies, surgical valve products and surgical accessories via independent development and collaboration with global partners. At MicroPort® CardioFlow, we strive to provide integrated therapeutic solutions for patients with heart valve disease, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.en.cardioflowmedtech.com